Tag Archives: polyglycolic acid suture
Chinese medical device market is actually composed of countless heroes “bow”
July 25, GE Healthcare announced that X-ray global headquarters will move to Beijing from the United States to open up China and other emerging markets. Last year, GE Healthcare has announced $ 2 billion in China\\ s plan, including the establishment of six R & D centers in China, a total of $ 500 million.
China, in the end how much of the fascination with the world\\ s number one medical device company that \"cordial\"? Recently through the VC, PE investment institutions such as the investigation, the reporter learned that the Chinese medical device market has become their investment \"new favorite\" .
Vast
Inspection tour of China\\ s medical device market, Sequoia Capital China partner Kui Zhou said the Chinese medical device market space is extremely broad.
According to him, China\\ s overall medical device sales volume growth in the past decade, nearly five times the rate of 21% annual growth in the last five years, the big market is the range of 20% of accelerated development.
According to Zhou Kui predicted that China\\ s medical device market, the current size is 100 billion yuan. \"Our total expenditure on the medical and health services accounted for 4.7% of GDP, while the developed countries, generally about 10%, which the United States reached 16% of China\\ s medical device and drug consumption ratio of 1:10, the ratio has been developed 1:1, China\\ s medical device industry, there are still large gaps in the market space for development is extremely broad. \"he said to reporters.
Medical device market, has attracted VC and PE investment institutions such great interest.
Figure days Cen Investment Partners, said the king, before the pharmaceutical company\\ s share of their total investment amount of investment of 70%, and from 2010 to now, the pharmaceutical investment has fallen to 50%, medical equipment and medical services of the investment ratio rose to 50%.
Capital Partners and IDG Ventures Suyang preferred that the main reason is that medical devices There is no monopoly in this area, therefore, private enterprises have many opportunities. At the same time, with Shenzhen Mindray Medical and diving medical market at home and abroad, led to a large number of medical device companies to capital markets, this is a good start.
Vice President Hu Minglong diving medical to reporters said that in 2011 China\\ s medical device market capacity also in 1000-120000000000 level, which compared with the world, only a very small piece of cake. The future, as new medical reform, the state began to encourage hospitals to charge through the clinic, in terms of medical equipment will be a new golden years, the opportunity is very good.
In addition, earlier this month at the \"Medical Device Industry Development Forum\", the Ministry of Health Planning and Finance Deputy Director Liu Diankui said, \"five\" strong support during the development of domestic medical equipment, the implementation of centralized bidding and purchasing, health care priority to the purchase of domestic equipment. Liu Diankui that health system reform for the domestic medical device industry, provides unprecedented opportunities and broad space for development, \"second five\" during the economic means to effectively guide the medical use of domestic medical equipment.
Structural opportunities
Sequoia Capital China partner Kui Zhou appears in the low-end medical equipment including medical equipment, supplies and health care of high value household goods. Now, some of the equipment slowly out of the hospital, into the family. The last three years, as Nuokang, will Kang, Kaifeng, billion Teng, new students, according to Rodriguez and other companies introduced products, have started from the hospital to home.
The growth trend will depend on many factors. Kui Zhou believes that the growth of low-end medical equipment, and related policy implications. The growth of high-value consumables, the increased demand associated with the rich.
Segments from the point of view, co-director of Intel Capital China, Wu Ronghui is optimistic about the medical equipment. She said, Intel set up after the number of medical departments, there is a large initiative, Intel and GE together to form a joint venture company, the main direction is the home medical equipment, portable, and can collect a lot of physical characteristics. In the future be possible to detect more chronic disease management and content to the family, community hospitals to promote, market space, which is they are more optimistic about the direction.
And Zhou Kui believe that the medical device industry, there are still structural opportunities.
He said that the industry is very characteristic, many small businesses make money, market, each company has not exhausted his means of competition, there is no great pressure to survive. It can be said medical device industry, the industry has not been fully integrated, not too many very powerful enterprises. Billions of dollars in business less than one hundred, in fact, you can see the concentration is very small. \"In the medical device industry, practitioners see the opportunities, investors can see that there is demand, there are opportunities for structural change.\"
Can expect that, in the market process, there will be companies emerge as industry leaders.
A market research analyst, told reporters, take diving medical, last year, the market scale of operation is 848 million yuan, while in the United States, Wall Street has an excellent micro-listed company called Sport, and its 1998 operating income There are 1.711 billion U.S. dollars, the gap is too big, like diving medicine, like Sequoia Capital investment Yi into the future will become a billion, billion, or even billions of enterprises, because the size of the market to allow such a company.
Husky hot runner gate side of the display using the new multi-class medical products
Husky Injection Molding Systems Fakuma exhibition in Germany this year to launch Ultra side of the gate hot runner technology and related products. The new runner is primarily designed for deep drawing products, such as straws, syringes, tubes and other small products. The original use straight gate cold runner injection molding products, the use of technology to meet the hot runner gate marks for quality and high demand.
Ultra side of the gate not only reduces the corrosion products of traces of high-altitude, improved gate quality, but also for the processors to provide a highly flexible design. Ultra side gate technology can help manufacturers to save material, reduce molding cycle, and in a wider temperature range products to achieve higher performance.
In addition, Husky has introduced a new generation of Ultra Sync-E electronically controlled valve gate technology, precision dry off can achieve high repeatability, the technique is ideal for clean room and all-electric injection molding machine.
GSM Association Global Mobile Awards recognize innovation in mobile health care
London, September 28, 2011 Xinhua GSM Association (GSMA) has launched its prestigious 17th Annual Global Mobile Awards (GlobalMobileAwards), designed for the mobile communications industry excellence, achievement and innovation to be commended. Global Mobile Awards 2012 2 月 28 日 (Tuesday) at Barcelona, ??the GSM Association\\ s Mobile World Congress (MobileWorldCongress) presented during the meeting.
Set up a new category of this award, intended for the whole mobile industry chain development and innovation awards, including applications, services, equipment and technology, with particular emphasis on innovation in the field of mobile health care.
MichaelO\\ Hara GSM Association chief marketing officer, said: \"The new mobile technology, embedded devices are an alarming rate, are increasingly being used in health care fields, resulting in a number of innovative applications such as remote monitoring, and we are Global Mobile Awards will be happy to expand health care coverage and may be life-saving breakthrough in global mobile devices, services and applications to recognize and display. \"
Mobile health care device manufacturers, mobile healthcare solutions provider, mobile network operators and chipset and module manufacturers are eligible to enroll in the new award competition.
Inquiries \"BestMobileHealthInnovation\" (Best Mobile Healthcare Innovation) Award, please click here. View a complete list of awards, standards and application details, please visit the Global Mobile Awards website: Deadline for the
“The new rural cooperative” calls for medical supply and demand balance
With the rapid economic development, China\\ s rural medical supplies in general has been greatly developed, the number of medical facilities in rural areas than in the past has also been substantially improved.
Township hospitals and village clinics, both in quantity and equipment, personnel, and more in the past have been greatly improved, which is the implementation of the new rural medical system and medical services to meet the needs of farmers played a catalytic role. With the increased income of farmers and national policy support, farmers actively participate in the new rural medical system, the participation rate reached 94%.
Rural health needs analysis
1 Analysis of farmers\\ income
With the rapid economic growth, China\\ s per capita income has steadily increased. Internationally accepted measure of family income, the Engel coefficient, in the past few years, China\\ s Engel coefficient showed an overall downward trend, in which the Engel coefficient of rural households from 58.8 in 1990 dropped to 41.0 in 2009. This reflects the general improvement of rural household income and living conditions improved.
(2) factors affecting rural health care needs
In addition to income factors affecting the demand for medical services of rural residents there are many factors, for example, transportation convenience, and cultural level of farmers, rural medical equipment as well as the aging population, environmental pollution.
(1) transportation of
At present, China\\ s rural traffic conditions than in the past has been greatly improved, some areas have achieved the \"village road.\" A convenient traffic conditions can effectively improve the farmers\\ demand for medical services.
(2) The cultural level of farmers
Culture can influence the level of a person made a decision. With the general cultural level of our population increase, the physical condition of the farmers for their understanding and level of quality of life has a significant increase, from the subjective improve medical and health services.
(3) rural medical condition
Rural medical conditions, including: the level of rural medical staff, medical facilities, as well as medical expenses. Higher level of medical personnel, medical facilities certain and reasonable medical expenses, to ensure that farmers demand for medical services.
(4) aging of the population
China has entered an aging society, changes in age structure, the average age will increase significantly from the objective to increase the people\\ s demand for medical care. And a young society will reduce the demand for medical services.
(5) environmental pollution
As we all know, the current global environment than 10 years ago has undergone tremendous changes. Environment has been damaged, a serious threat to human survival. Poor living conditions gave rise to a greater threat of disease. Corresponding demand for medical services will also increase.
\"The new rural cooperative\" with the rural health care supply and demand analysis
Because of asymmetric information between doctors and patients as well as the level of rural health status, lack of farmers\\ right to choose medical services. Today, China mainly through the new rural cooperative medical care for rural residents to protect and reduce their health care burden. Farmers have to go to the designated patient medical health insurance unit, which contributed to the cooperative medical supply-side advantages.
\"The new rural cooperative\" to protect illness was mainly Paul inpatient medical services, and service needs of ill health, mainly in the county level or above designated cooperative medical designated hospitals, these hospitals are likely to cause a shortage of medical services, inadequate supply of . A direct consequence of the inadequate supply of health care transaction costs in disguise, leading farmers in the reduction of benefits from the medical cooperation, reduce the system gain. Therefore, the \"new rural cooperative \\ implementation will increase above the county level the number of designated medical institutions for medical care, thereby reducing the township hospitals and village clinics needs.
Development proposals in rural health care
1 step up publicity efforts to guide farmers to voluntarily participate in the \"new rural cooperative.\"
Farmers to voluntarily participate in the new rural cooperative medical care, we must first understand the \"new rural cooperative.\" Government to increase the \"new rural cooperative\" policy advocacy efforts, by farmers from the \"new rural cooperative\" in the typical case of access to affordable, so that farmers really recognized that participation in the \"new rural cooperative,\" the importance of the \"new rural cooperative\" system enjoys popular support, so that farmers understand and accept. We should actively guide farmers to change the traditional ideas, eliminate ideological concerns, continue to strengthen the awareness of risk diversification, voluntary participation, \"the new rural cooperative.\"
It should be said that China, after years of publicity and promote the work of rural residents generally accepted the new rural cooperative medical care policy, but as to how the specific level of compensation and compensation, the majority of farmers still unclear. Must step up publicity efforts, the highly professional user-friendly way to explain the policy to make clear the majority of farmers.
(2) to enhance the standard management of medical services
The Government should strengthen the designated medical service behavior and the regulation of drug prices, medical services and medicines as a special commodity, its difficult for farmers to make a choice, you need government regulation. The Government should strengthen the rural health institutions, medical personnel, health technology and other aspects of access management, adherence to quality and price of drugs, medicine, rational drug use, medical service prices and charges behavior management and supervision, to crack down on counterfeit and fake health advertising, medical drug farmers to ensure safety and increase farmers\\ new rural cooperative \"system of trust.
At the same time, strengthen the non-government private health sector management, improve and perfect the relevant laws and regulations, laws and regulations such as the health care market, pharmaceutical market laws and regulations, health laws and regulations of the talent market, so as to adapt to the rapid development of medical and health development, security healthcare industry healthy and orderly growth.
3 to improve funding levels, improve the financial management mechanism
In the \"new rural cooperative\" fund-raising process is prone to the problem of insufficient funding, the government needs to improve the \"new rural cooperative\" level of funding, especially in poor areas appropriate for increased subsidies, while actively raising the Social Fund. Fund operations in the process, prone to misappropriation of funds and abuse of other issues.
Therefore, while the government should expand the financing channels, making the farmers from the \"new rural cooperative\" in the real tangible benefits, so as to attract greater demand; the other hand, should strengthen the management of funds, so that the whole cooperative medical care system public, and to prevent incidents of corruption, to ensure the safe operation of medical funds.
China s market status of medical and health information
China s medical industry including hospitals, clinics, community health service centers (stations), clinics, nursing homes, maternity and child care, specialist disease control agency, CDC, medical research institutions, administrative agencies at all levels of health care, etc. medical and health institutions. According to statistics released by the Ministry of Health, 2008, the number of 278,337 domestic home health agencies.
According to the Ministry of Health published "Hospital hierarchical management approach", the state hospital management at different levels, according to the hospital functions, tasks, facilities, conditions, technical capabilities, quality of medical services and the overall level of scientific management conditions, the hospital is divided into One, two, three; each level is divided into A, B, C third-class, grade level to the highest level.
In addition to hospitals, medical and health institutions in China including hospitals 39,860 homes, outpatient clinics (the) 180,752 home, maternity and child care (the / stand) 3,011 homes, CDC 3,534 homes, 1,310 homes specialist disease control agencies, nursing homes ( The) 210, community health service centers (stations) 24,260 home, the Health Authority and other agencies 3,013 2,675 family homes.
China Yixie merger will give rise to giant
In the long term China\\ s medical device market has great potential, the current industry is the development of the critical point in the integration. And professional development in the integration process will give rise to future industry giants.
At present the medical device industry have the following investment highlights:
Chinese medical device industry in the development of the critical point integration, specialized foster mergers and acquisitions market segments leading, comprehensive merger gave birth to the industry giants. Eisai mainly from the primary start-up phase to the categories of the initial stage of expansion, to the 1990s, private capital to promote structural changes in phase, the Chinese medical device industry to complete the original technology and capital accumulation, and initial implementation of product structure adjustment and regional industry layout. 2006, the new medical reform started, the industry entered a new historical period. Diversification strategy demands, fierce competition and capital strength to become a catalyst for industry consolidation in the industry and the health characteristics of the joint action of the external environment, enhance concentration and diversification trends form. China\\ s domestic medical device companies through mergers and acquisitions, to promote the industry to focus on. And professional development in the integration process, the emergence of more market segments leader, and gave birth to the future of the industry giants.
Future development of the strategic positioning decision, first and business expansion is expected to become industry giants. Integration period of development, China has three medical device companies will be the development of pattern choices: 1) focus on market segments, segment leading achievement; 2) expansion through mergers and acquisitions, to become integrated giants; 3) advantages of using technology to achieve Medical electrical integration. Focus and diversity are essential, we believe that diversity, and actively expand the enterprise to integrate more want to be the winner. Mindray Medical, WEIGAO, diving medicine, music has universal health care through joint ventures, mergers and acquisitions to diversify and become an integrated leader. Minimally invasive medical care, Comfort Medical, creation care, nine security health care, universal health care Yang, Xinhua Medical is the leader segments. Wandong Medical, although only focus on one segment, but behind the development of China Resources Group carries the medical device industry expectations.
Industrial upgrading trend, China\\ s medical device industry from traditional manufacturing to high-tech development. Manufacturing process is the development of China-based medical device industry, through the accumulation of products has established a complete system, and established in the field of low-end product a pivotal position. China Medical Device actively upgrading technology for domestic market and external industrial transfer opportunities. Product quality, enhance the technological structure makes the Chinese enterprises in the care, medical imaging equipment, laboratory equipment and clinical areas such as minimally invasive treatment to obtain remarkable results. Innovation and development of an irreversible trend, computed tomography, magnetic resonance, cardiac electrophysiology devices, artificial joints will be the next occupied the high ground.
Chinese medical device market has great potential to sustain rapid growth. Global medical device industry growth than the pharmaceutical market, the future will maintain 10% -15% compound growth rate. While the developed countries accounted for 78% of the market, however, developing countries represented by China\\ s market is experiencing rapid growth, the accumulation of the cost benefits of upgrading the industrial chain and R & D position. Rising health care costs, rising health awareness and spending power will be a positive factor to promote the development of the industry, pharmaceutical industry and health system to inject additional momentum, as the release of pent-up demand, and potential future open space induced force. Rebalance the allocation of resources, upgrading and industrial transfer of internal and external dynamics are intertwined, the Chinese medical device industry compound annual growth rate will remain at 20% -30%.
Industry risk:
1) the recession, cut spending may inhibit the high-end export market demand; 2) appreciation of the renminbi to weaken China\\ s global competitiveness of manufactured products; 3) medical equipment production and sales in all countries are subject to strict regulation, policy changes could significantly improve the manufacturing costs; 4) foreign large medical device companies to accelerate into the Chinese market, domestic brands and increased competition may drive down industry profits.
Large medical device companies will benefit from the new GMP, and infrastructure expansion. As China\\ s rising industry standards, as well as generic manufacturers from around the world for cost-effective production of the growing demand for equipment, medical and East Xinhua Teflon for long-term major medical device companies are optimistic about growth prospects. We reiterate our positive view of Xinhua medical reasons in 2011 after the implementation of GMP in the new company\\ s profit is expected to achieve strong growth of 96.8%, also with a strong R & D capabilities, the company will continue to introduce new products and services.
Cost and speed of medical supplies in the market is crucial. We believe that domestic enterprises have the potential to seize market share from the hands of transnational corporations. By focusing on the domestic manufacturers are developing high-margin products to the industrial chain forward. Creation of medical and minimally invasive medical and other companies in order to remain competitive in the bidding, is working through a range of products, rather than a single product into the joint device market. However, due to poor product quality reputation, the market can accept the joint product of domestic concerns still remain.
Sales market is expected to grow strong, but margin pressure is a new concern factors: First, for the second half of 2011 to prepare the tender. Our research enterprise of China\\ s medical device industry, long-term growth potential of the overall positive view, because most companies believe that sales in the next 2-3 years, demand will remain strong, with an annual compound growth rate of 25-30%. But the tender is the industry\\ s profit margins of uncertainty facing the pressure of the main policy. Our research enterprise that China may begin in the second half of 2011 high-end medical equipment and supplies for the tender at the provincial level, in order to control overall health care costs, because the Government believes that the tender price to manage areas in central and easy to supervise. Development of many new products are waiting to enter the market before the scope of the tender, and businesses are expected when the next round of bidding the price will be lowered.
Improve Medical
Capacity expansion to enhance the performance
Japan Securities Research report, the company is home to the hospital for more than three leading provider of vacuum blood collection system, the whole has been covered more than 70 countries and regions worldwide, nearly 2,000 medical institutions to provide products and services. The domestic market: in 2008 in Guangdong, Beijing and Shanghai to the three hospitals with more than the coverage of such products were 77.33%, 20.29% and 24.44%, and the hospital for more than three such instruments of domestic consumption of the total amount of the instrument more than 50%; foreign markets: the company\\ s products have been certified with Germany and other countries, follow-up product is currently ongoing U.S. FDA approval, although the short-term base may be relatively low, the performance by leaps and bounds can be expected.
Estimated 2011, 2012 and 2013, respectively, the main business revenue growth of 89.33%, 44.38% and 20.98%, corresponding to EPS of 0.29 yuan, 0.45 yuan and 0.56 yuan, corresponding to 2011, 2012 and the current price-earnings ratio of 46.55 in 2013 , 30.00 and 24.12 times the recommended rating given to the proposed bargain-hunting interest.
Extension and expansion worth the wait
Societe Generale Securities research report, in the short term, oral health care is the company\\ s core business, but in the long term, the company is not confined to the mouth area, and intends gradually to maternal and child health, infertility, orthopedics, and other specialty hospitals to expand. Company Management Group is committed to a major hospital, medical service area for more investment.
Not consider the impact of future acquisitions, a slight increase in the company\\ s profit forecast, estimate the ESP in 2011 -2013 were 0.45,0.60 and 0.80 yuan, the rapid growth of oral health care services, extension of type-expected merger is expected to become the catalyst for the company the current market value of 3.2 billion increase in the long run a larger space, to maintain \"recommended\" rating, the proposed bargain configuration.
Dunlop Medical
Optimistic about the consumables business
Minsheng Securities research report pointed out that because the base has a large sales stand, first half of the company\\ s stent business sales growth of 17%, lower than expected first half of this year\\ s prices slightly lower bracket. According to the foregoing, will stand to adjust the growth rate from 30% to 20%. Although the company\\ s stent business growth has slowed, but the price pressure for increased supplies clear, steady growth in congenital heart occluder. In 2011-2013 the company expects EPS were 0.62,0.77,0.94 yuan, to maintain \"cautiously recommended\" rating.
Diving medical
Competitiveness of obvious advantages
Hong Yuan Securities research report, listing performance of sustained high growth since the root cause of the company\\ s strategic direction in the right, in brand development, management, products, channels and other aspects of the company\\ s competitive advantage is difficult to be crossed to form a comprehensive competitiveness. This will ensure the competitiveness of the company\\ s future still in accordance with the previous model years, rapid development, continue to control costs to maintain the competitiveness of products, channels and further develop and expand market share, R & D investment to ensure continued introduction of new products, and then copy the old channel of its own products of success.
The company expects earnings per share 2013 2011 0.62 yuan, 0.91 yuan, 1.29 yuan, the current corresponding to PE were 47 times, 32 times, 22 times, we believe that most medical devices company is long-term investment potential of companies, is currently estimated the level of reasonable value, given buy rating, target price $ 40.
Capital fought over health care chain
Health sector of the capital market in 2010 was a very eye-catching: inside and outside the healthcare industry as an initial public offering (IPO) one of the largest number of four industries; the average IPO book industries and enterprises the highest return on investment is the healthcare industry industry, the average investment rate of return of 18.68 times.
And health care services throughout the healthcare industry, the growth plates are also outstanding shares. Fifth China Healthcare Industry Investment and Financing Summit disclose figures, from the sub-industry point of view, the original thriving pharmaceutical industry, accounting for 70% of the total financing, to 2010 the proportion fell to 50%, the remaining significant growth from the medical services and medical equipment, especially the former.
\"China\\ s medical needs are long-term sustainable growth, unlike the automobile, telecommunications and other sectors of the growth curve is S-shaped, up to a certain peak that is the turning point, while the medical industry is basically showing linear growth, we are particularly optimistic about the industry.\" direct investment in the company general manager Jin Chen, Yu said at the summit.
Number of private medical institutions to find financing, venture capital for high-quality projects, listed companies and multinational corporations seek seek acquisition opportunities, a variety of needs in the marriage of capital and exchange platform for the medical industry on the corner. And wish to take a slice of the capital market more and more medical institutions. Legend Capital, General Manager Liu Zehui this proposal, \"the leadership of medical institutions bear the greatest risk and responsibility, especially after the introduction of investors, the pressure will be greater, should the purpose of financing, future planning should think carefully, do not order financing and financing. \"
As the public hospital system, reorganization of the detention policy, institutional investors have to take a detour, only bent on private medical institutions. Avenue CapitalGroup Zan Tao, executive director, said: \"Avneue funds invested in the UK a large 1,500-bed hospital, while in China there is no such opportunity. China is now the policy to the social capital is indeed a good imagination, but the tax , human resources, incentive compensation and other supporting policies are not in place, investors have a high-end medical experts can not enter the large public hospitals, not only turned to a private high not low secondary hospitals as investors involved more deeply in love with the privatization of public hospitals, investment the opportunity. \"
Specific to health care institutions, investors place great emphasis on investment targets of the management team. CDH Executive Director Wang Hui said: \"We invested a total of four medical institutions in the Hospital is the hospital, house, equipment in place, the specific operation to be enforced, the time involved in the implementation process, quality of service and other details as investors We have no way to help, but also they have the management strength of the hospital. \"
Shenzhen Capital Group, Liu Gang, general manager of Beijing also shared: \"We are investing in the hospital, tend to find the best professional management team, want to have a strong core management synergy, because the highly specialized treatment services, There should be a core team. \"
Investment institutions to invest funds into the object, the two form a close community of interests, the former often also provide additional support as a value-added services.
Chen, Yu introduced the gold companies to invest in two medical institutions, compared to other industries, investment in the medical industry to spend on doing up the value-added services to help invest in the top three hospitals and medical institutions to establish co-operation, a large hospital for the medical expert resources , and even help them replicate the chain of medical institutions, participation, including holding a license, looking for an apartment, to get to such trivial things.
In fact, the medical services in the healthcare industry\\ s share is not large. \"If the health care equivalent to hospital, then the investment opportunities in China are very small. The gradual improvement in the external policy environment, investors may wish to invest in some proper extension of the border, focusing on the entire health industry chain, which is still very pragmatic tactics. \"Liuze Hui said.
Medical device industry merger wave struck and ophthalmic diagnostics into the land of mergers and acquisitions
Perhaps the medical device industry is facing a wave of mergers and acquisitions, many companies want from the weak economy to get out, and thus embarked on rapid development. Meanwhile, the search for potential acquisition targets will no doubt make the company earn that respect. In recent months, the medical device industry mergers and acquisitions to accelerate significantly, the company can increase revenue quickly became the medical device industry, large and small transactions a beautiful landscape.
Next year, the field of diagnostics and Ophthalmology will be active in mergers and acquisitions area, Johnson & Johnson, Abbott Laboratories, Baxter International Inc. and Medtronic companies are seeking opportunities. However, at BMO Capital Markets Michael Neuberger is that: \"Large mergers and acquisitions continue to increase, but the transaction has no new ideas.\"
Medical industry in 2009 by the economic crisis and the acquisition of new market concerns about the impact of the U.S. health care law, the first half of the trading value of the medical device industry over the year 2009. According to Ernst & Young (Ernst & Young) recent report shows that Europe and America during the first half of this year\\ s 89 deals worth $ 16.9 billion, while the year 2009, 172 deals worth 15.7 billion U.S. dollars. The first half of this year, the total transaction value does not include the Swiss drugmaker Novartis to $ 28 billion to complete the United States acquired from Nestle\\ s Alcon ophthalmic products (Alcon).
Since the loss of private insurance coverage and deductible up to see a doctor cause began to decline in patients, medical device manufacturers have to seek new revenues and profits declined the opportunity. Some companies began new changes, rather than blindly stick to those who are already mature market for medical devices such as pacemakers and hip replacements, the market growth has been very slow, only the single digits.
Recently, the orthopedic device maker Stryker Corporation (Stryker Corp) announced that $ 1.5 billion will be to buy Boston Scientific Corporation (Boston Scientific Corp) neurovascular departments, to produce for the treatment of stroke, aneurysms and other vascular diseases of the equipment. U.S. St. Jude Medical Company (st.jude medical) will also be $ 1 billion buy equipment manufacturing structural heart defects competitors AGA Medical Holdings. But Neuberger said the stock valuation is attractive to stimulate the medical device industry generated more transactions.
This year\\ s largest medical technology trade of medical equipment manufacturer Covidien plc for $ 2.6 billion rapid acquisition of the neurovascular and peripheral vascular disease products manufacturer ev3 Inc.
President of Covidien Covidien plc, said three years ago, medical device and drug manufacturers U.S. Tyco International Ltd. (Tyco International) on blood vessels in the area looking for acquisition targets, but the size of the future may be in the $ 1 billion.
Johnson is also actively seeking acquisition targets, $ 480 million in September to complete the stroke maker Micrus Endovascular product acquisitions, most recently prepared for $ 2.4 billion bid for Dutch vaccine maker Crucell. Investment advisory firm Peter J. Solomon, vice president Frederick Frank predicted that the major medical companies such as Johnson & Johnson and Abbott will broaden the portfolio has more moves. He said: \"The large companies in the pharmaceutical and medical technology business at the same time be changed, further developed into a diversified company, I think this is very wise.\" Neuberger speculated that M & A activity in the diagnostics area will be very active, mainly by the individual medical and testing can help patients determine whether to accept the promotion of more effective treatment.
Medical potential opportunities abound resin
With the continued double-digit sales growth and strong financial reserves, now there are many medical materials companies are planning to carry out the various acquisitions. Applications in the medical industry for a wide range of resin products also increased investment. Various types of resin products for the medical industry demands further improved, more secure, user-friendly and lightweight will become the future development direction. More and more material suppliers continue to make breakthroughs, provide the market with excellent performance even more material.
Grasp the opportunity frequent acquisitions of foreign companies
June 7 at the eastern opening of the New York medical design and manufacturing exhibition, from Ohio, USA, PolyOne\\ s marketing director Larry Johnson, reporters interviewed and said: \"PolyOne is particularly strong and adequate funds, we have been working to find better, more effective ways to expand mergers and acquisitions company size. \"
Johnson added: \"Now, PolyOne of effort looking for is complementary to our existing business to the company so the company can help us be more efficient new materials development and utilization, expand the size of the business, and medical industry to provide appropriate services. Figuratively speaking, the company will become the ladder to a higher level course, you can also get a lot from PolyOne beneficial resources such cooperation must be a win-win. \"
Coincidentally, MedPlast as a company specializing in medical molding business exhibitors about the next 12 months in the development of targets, told reporters: \"We will in the next 12 months to complete an acquisition, it will be our the company\\ s first plant outside the United States. \"
MedPlast sales and marketing executive vice president Mike Farrell said: \"Three years ago, we had established the acquisition plan and we are looking for worldwide mergers and acquisitions of our project to expand the business support market functioning well. \"
Investment in favor of U.S. and European companies look accurate low-cost countries
UPG International\\ s vice president of sales and marketing Matt Landon said in the short term there will be no new UPG acquisition. The fourth is located in Suzhou, China plant will be built from the start in August this year, to be completed by 2012.
In addition, he said: \"this year in the United States increased the number of clean Chicopee plant, and plans to expand the factory in Minneapolis next year. In addition, the company acquired another overseas factories into the plan preparation stage. \"
\"In western China and some Eastern European countries, we already have a considerable scale of production lines. And, sustained double-digit sales growth.\" Matt Langton added: \"If by now the trend continues, I very happy to see in these areas can open up more low-cost production base. \"
According to reports, the well-known supplier and manufacturer of precision molded GW Plastics is expanding its overseas medical services market. GW Plastics company in Costa Rica\\ s first joint production line has been put into operation in August. GW Plastics Company invested a total of more than a year ago, $ 2 million renovation of its mold manufacturing plant upgrade. And two years ago, GW Plastics has established a special pre-product R & D center.
It is reported, GW Plastics Company may in the same industrial park next year, a nearly $ 3 million investment in new projects.
GW Plastics business development vice president Larry Bell told reporters in an interview revealed: \"Costa Rica\\ s plant is crucial for us, it is directly related to our development prospects for many companies, reluctant to to invest in China or Mexico and other countries, they believe there is no way these countries to meet their expectations but in our opinion it is precisely a great opportunity this provides us with a low-cost development of land is not cultivated. \"
Emphasis on material recycling companies for sustainable development
According to foreign media reports, many companies are now working to develop recyclable materials, to help original equipment manufacturers and medical device manufacturers to reduce production costs or avoid risks.
Mark is located in Arlington, Vermont molding Co., north of the medical industry and operations president Jeff Sang Pule told reporters: \"Clients often want to partner companies to understand more clearly the case, thereby reducing the initial audit on the of work. \"
Mark Molding Co., Ltd. on its official Web site of a new sustainable development section. Jeff Sang Pule explained: \"This section allows us to directly understand our customers are doing.\" This is a public document, every person concerned about the mark you can always click access.
This is Mark molding Co., Ltd. is committed to providing environmentally friendly, recyclable materials, the underlying causes. Altuglas company is located in Bristol, Pennsylvania. Carmen Rodriguez is Altuglas\\ s resin products in the international business manager. She said in an interview: \"We are looking for a suitable alternative materials for the future sustainable development of viable solutions.\"
It is reported that, Altuglas company has launched a new series of bio-based transparent thermoplastic polymer, the main component of polylactic acid and mixed polymethyl methacrylate.
Rodriguez added: \"We have produced a new type of glass Rnew resin series, intended to replace the existing non-renewable materials, polycarbonate, etc. The material has a high transparency, strong impact resistance and chemical resistance. suitable for use in drug delivery systems, blood reservoirs of liquid reserve system. \"
\"We can meet customers\\ different needs and expectations.\" Delhi Ge Zi said, \"By the introduction of PLA PMMA, into the high level of renewable carbon, to get the flow of melt temperature, thus improving the material processability. To achieve unprecedented chemical resistance. \"
In addition, Rodriguez said: \"We are committed to finding the best materials, reduce material consumption, improve performance and simplify the production process to enable them more competitive in the market has been greatly improved.\"
Emphasis on material security resin huge space for development of medical materials
Medical timber can not be taken lightly, for the security has a very high demand. Materials R & D and production, must be to the safety of the material itself, as an important indicator of chemical stability.
SABIC Innovative Plastics\\ healthcare industry marketing director Tom Austria. Brian said: \"SABIC\\ s Ultem HU1004 polyetherimide resin products have passed the third-party company\\ s sterilization testing and only safe and reliable resin products can With its excellent performance in more medical equipment service companies. \"
Tests show that it has a very superior performance. ULTEM HU1004 PEI resins, at low temperatures can be used normally. In addition, hydrogen peroxide gas plasma, gamma radiation environment can be effectively sterilized. This provided an effective means for the enterprise. For medical equipment and other electronic applications manufacturing enterprises, this is good news.
It is reported that Nypro Clinton, the company also increased its headquarters in the development of medical device design center. Nypro Medical Group President Ray Grupinski said confidently: \"We are visionary, very early development of the medical industry is very optimistic about the prospects and identify relevant resources, which allows us to get more quickly than the competition business.\"
It is understood that the Food and Drug Administration has issued relevant documents, medical device manufacturers of pressure. Product performance, quality threshold continue to be improved. This requires a constant self-improvement to the use of market demand, with particular emphasis on product safety and stability. On this issue, many corporate executives have the same views and reached consensus.
Editing Conclusion:
After 10 years of development, resin products, applications in the healthcare industry has grown from drugs, pharmaceutical packaging and drip bottles, disposable equipment, extended to non-disposable surgical instruments and other equipment. Today, the resin products in the infusion, anesthetic equipment, catheters and packaging and other applications have made new progress.
Throughout the development of European and American business executives for industry analysis and commentary, we find that the market has unlimited potential. However, the medical industry security requirements for the material is very high, should not be underestimated. Because it is directly related to health and safety of product users. In other words, medical materials must be guaranteed their safety on.
Epidural can be used for endoscopic treatment of intractable low back pain
Recently, Shandong Provincial Hospital Pain in the internationally renowned professor of medicine, the Dutch expert Robert Van Senventer minimally invasive surgery under the guidance of Professor Song Wenge and professors work together successfully as a FU Zhi-jian intractable low back pain patients completed the C-arm X-ray guidance epidural endoscopic surgery. Postoperative left lower extremity pain, numbness, cold flu symptoms, postoperative rehabilitation, the symptoms without recurrence. This innovative surgical procedures was a complete success.
Patient was a 33-year-old young woman, three years ago left hip, hip pain, accompanied by left lower extremity numbness, cold, sedentary, and fatigue symptoms increase, a slight relief after bed rest. To relieve pain, the patient went to many hospitals for treatment, the effect is not obvious, and later came to the clinic, admissions experts \"lumbar disc herniation,\" admitted to hospital. The experts studied and discussed in detail the patient\\ s condition, agreed to take epidural endoscopic surgery can get the best results. In view of this country has yet to carry out surgery, laparoscopic surgery has invited in the epidural area of Dutch experts accomplished deep Professor Robert Van Senventer guide to the hospital.
During surgery, the doctor first with 1% lidocaine in patients with sacral hiatus center for a Picchu, Picchu by piercing the skin, and gradually infiltrates into the sacrococcygeal ligament, then a switch 18G Tuohy epidural needle, through the sacral piercing the sacral hiatus to the head in the direction forward. From a lateral perspective using X-ray to confirm the needle in the sacral angle and position is correct. Then injected through the epidural needle two milliliters of non-ionic contrast agent, and then X-ray shows including nerve roots, including fat and epidural adhesions with anatomical images, lumbar 2 / 3 level of the left side of the filling defect, indicating that patients with epidural adhesions. X-ray monitoring under the guidance of epidural needle by gently twisting the head, until the guide wire into the lesion site, out of Tuohy needle. Puncture the skin with a scalpel to the sacrococcygeal ligament expand, move forward along the guide wire and guide sheath dilator, into the sacral canal, the withdrawal of the guide wire and dilator, only the guide sheath remains in the sacral canal, with 10 ml saline flush guide sheath side arm, and then with a fiber optical endoscope guiding tube device through the guide into the sacral
Tube, oriented along the optical fiber endoscope tube will slowly into the epidural space, and then to the lesion, into the brush by the side of the tube-shaped guide wire under direct vision in the endoscopic removal of adhesive materials, and in the target area injection of corticosteroids and neurotrophic drugs.
Completion of the operation shared two hours after the patient left hip, hip pain and numbness of the left lower limb cold quickly disappear, after getting out of bed without any symptoms, surgery in patients with only a little anesthetic, postoperative position not limited, to normal activity, 4 days after surgery patients were discharged.
According to the renowned pain expert Professor Song Wenge introduction, laparoscopic epidural is a three-dimensional, dynamic, visual color imaging system, can look directly at the spinal structure. As a special diagnostic tool, which can include special clinical treatment, including surgery, provide the basis for the diagnosis and treatment of chronic low back pain of the disease can play a unique role. Experienced doctors can aid in identifying the epidural endoscopic some potential causes of pain such as epidural adhesions, nerve root edema, epidural compression, anatomic variations, nerve root cystic degeneration, vascular and abnormal. Endoscopic diagnosis of either look into the epidural lesions, but also directly to the lesion and injection line adhesiolysis treatment. According to foreign prospective clinical trial data show that endoscopic epidural lysis of adhesions down, while injection of hyaluronidase in the target area, such as corticosteroids and ozone, which can effectively relieve post-operative epidural adhesions caused by chronic low back pain, is effective and lasting. Meanwhile, CT, MRI examination can not clear the cause of the complexity of low back pain cases, the application of epidural endoscopic treatment has its unique advantages.